Beidujia pharmaceutical industry has applied for delisting decision due to twists and turns in the way of resumption

[industry trends of pharmaceutical network] Beidou Jia pharmaceutical recently announced that the company received a letter from the stock exchange on November 15, 2019, indicating that the trading of the company's securities had been suspended since September 27, 2018, and the trading could not be resumed before September 26, 2019, so the GEM Listing Committee decided to cancel the listing of the company (delisting decision) according to article 9.14a of GEM Listing Rules According to the letter, the post listing date of the company's shares will be November 29, 2019, and the company's shares will be cancelled from 9:00 a.m on December 2, 2019 After considering the legal and professional opinions, the company has submitted a written application to the Secretary of GEM Listing Review Committee of SEHK to review the delisting decision in accordance with Article 4.06 (2) of GEM Listing Rules on November 22, 2019 In fact, when beidujia pharmaceutical industry will resume trading is concerned by the industry On September 27, 2018, beidujia pharmaceutical announced that since the trading of the company's shares was suspended on September 27, 2018, the group has continued its daily business operations At that time, the company believed that as of the announcement date, it had reached the conditions for resumption of trading, and the company was seeking confirmation from the stock exchange Later, it was said that once the resumption plan and the resumption schedule were determined, the company would comply with the relevant GEM Listing Rules, including issuing a public announcement to disclose the relevant resumption plan and the resumption schedule, seeking the approval of the stock exchange, sending a circular letter to shareholders and holding a special meeting of shareholders to approve the transactions to be carried out under the resumption plan In March, beidoujia pharmaceutical released a notice saying that at present, the Beijing court of China is further processing Wang Shaoyan's property and the company's equity held by Wang Shaoyan and Wang Yan The Chinese lawyer of the company informed the Beijing court of China that on the date of announcement, the Beijing court of China did not list the company as the person to be enforced In addition, in February 2019, the company informed the people's Court of Jiaohe City, Jilin Province, and found that the real estate in Jilin City under the company's name was sealed up by China Jiaohe court At present, the company is committed to determine the resumption plan and the resumption schedule as soon as possible In April this year, beidujia pharmaceutical announced that the company received a letter from the stock exchange dated April 3, 2019, in which the Stock Exchange listed the following additional guidelines for resumption of trading for the company: announce all outstanding financial performance and resolve any audit amendments At present, the company is committed to determine the resumption plan and the resumption schedule as soon as possible In addition, the company's shares continue to be suspended It can be said that the road of Beidou Jia pharmaceutical industry's resumption is twists and turns According to the data, beidoujia Pharmaceutical Co., Ltd is a listed company that applies leading technology to provide comprehensive health services The company is based on health medicine big data services, Chinese herbal medicine planting and Chinese herbal medicine And medical product trade and other businesses, gradually completed the industrial ecological layout, and developed into a comprehensive industrial development group centered on Beidou health big data, covering the health care service ecosystem, Beidou big data application ecosystem, and traditional Chinese medicine business ecosystem According to the financial report data, for the nine months ended September 30, 2019, the turnover of the company was 63097000 yuan, a year-on-year increase of 377.72%; the owner of the company accounted for a loss of 2188000 yuan, a year-on-year decrease of 86.6%; and the loss per share was 0.25 points According to the company, the board will focus on existing business growth and will continue to explore and evaluate new business and investment opportunities that may bring good potential or long-term benefits to the group and its shareholders